Tercica Announces Results From Increlex(R) IGFD Patient Registry And Other Increlex(R) Studies At The 90th Meeting Of The Endocrine Society
Tercica, Inc. (NASDAQ: TRCA) announced the first results from the Increlex® Growth Forum Database (IGFD) Registry in two posters presented at the 90th annual meeting of the Endocrine Society in San Francisco. Increlex® (mecasermin (rDNA origin) injection) is currently approved in the United States for the treatment of severe Primary IGF-1 Deficiency.
More: continued here
Filed under: Endocrinology on June 19th, 2008